Research ArticleArticle
Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-tetrahydro-1-naphtylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels
David Paul Jenkins, Dorte Strobaek, Charlotte Hougaard, Marianne L. Jensen, Rene Hummel, Ulrik S. Sorensen, Palle Christophersen and Heike Wulff
Molecular Pharmacology March 1, 2011, mol.110.069807; DOI: https://doi.org/10.1124/mol.110.069807
David Paul Jenkins
Dorte Strobaek
Charlotte Hougaard
Marianne L. Jensen
Rene Hummel
Ulrik S. Sorensen
Palle Christophersen
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-tetrahydro-1-naphtylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels
David Paul Jenkins, Dorte Strobaek, Charlotte Hougaard, Marianne L. Jensen, Rene Hummel, Ulrik S. Sorensen, Palle Christophersen and Heike Wulff
Molecular Pharmacology March 1, 2011, mol.110.069807; DOI: https://doi.org/10.1124/mol.110.069807
Research ArticleArticle
Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-tetrahydro-1-naphtylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels
David Paul Jenkins, Dorte Strobaek, Charlotte Hougaard, Marianne L. Jensen, Rene Hummel, Ulrik S. Sorensen, Palle Christophersen and Heike Wulff
Molecular Pharmacology March 1, 2011, mol.110.069807; DOI: https://doi.org/10.1124/mol.110.069807
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement